Please login to the form below

Not currently logged in
Email:
Password:

Valeant extends Allergan bid deadline to end of 2014

Acquisition saga carries on beyond original August 15 deadline
Valeant Pharma logo

Acquisition hungry Valeant Pharmaceuticals is continuing in its pursuit of Allergan by extended the bid deadline to December 31, 2014.

Valeant had initially given Botox makers Allergan a deadline of August 15, 2014, to make a decision on its $53bn offer, which was proposed in June.

The announcement extends further the saga between the two companies, which began in April this year with a rejected $45.7bn bid from Valeant – a company that is intent on breaking into the top pharma companies in the world primarily via a series of takeovers.

Since then Allergan, which also has successful, neurosciences and medical aesthetics businesses, has repeatedly turned down various offers from Valeant, forcing negotiations to turn hostile.

Allergan has voiced its concerns over Valeant's business model of growth by acquisition and streamlining and has initiated several efforts to ward off its potential suitor.

This includes plans to cut its workforce by 13 per cent to convince shareholders of the company's independence.

And at the beginning of August Allergan filed a lawsuit in the US that claims Valeant's hedge fund backer Pershing Square Capital - and its owner Bill Ackman - had fraudulently built up a stake in the company ahead of Valeant's first public offer for Allergan while “fully aware” of the Canadian pharma company's takeover intentions.

Article by
Thomas Meek

18th August 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics